Silence Therapeutics (SLN) Short-term Investments (2020 - 2026)

Silence Therapeutics has reported Short-term Investments for 5 years, with the latest figure at $64.4 million in Q1 2026.

• Quarterly Short-term Investments fell 10.09% year-over-year to $64.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $64.4 million (down 10.09% YoY) and the FY2025 annual result came in at $73.8 million, up 14.05% from the prior year.
• Short-term Investments declined to $64.4 million in Q1 2026 per SLN's latest filing, from $73.8 million in the prior quarter.
• Over five years, Short-term Investments peaked at $73.8 million in Q4 2025 and troughed at $20.2 million in Q3 2025.
• A 4-year average of $57.7 million and a median of $64.7 million in 2024 frame the typical range for Short-term Investments.
• The sharpest annual moves came in 2024 and 2026: Short-term Investments jumped 75.11% in 2024, then dropped 10.09% in 2026.
• Over 4 years, Short-term Investments stood at $37.0 million in 2023, then surged by 75.11% to $64.7 million in 2024, then climbed by 14.05% to $73.8 million in 2025, then retreated by 12.75% to $64.4 million in 2026.
• According to Business Quant data, Short-term Investments over the past three periods registered $64.4 million, $73.8 million, and $20.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.